Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in advanced gastric/gastroesophageal junction adenocarcinoma
NCT04342910Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui. Started Sep 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04342910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342910.